OS Therapies Incorporated (NYSEAMERICAN:OSTX) Short Interest Up 35.6% in January

OS Therapies Incorporated (NYSEAMERICAN:OSTX) was the recipient of a significant growth in short interest in January. As of January 15th, there was short interest totaling 845,317 shares, a growth of 35.6% from the December 31st total of 623,422 shares. Based on an average trading volume of 931,073 shares, the days-to-cover ratio is currently 0.9 days. Approximately 2.7% of the company’s stock are short sold. Approximately 2.7% of the company’s stock are short sold. Based on an average trading volume of 931,073 shares, the days-to-cover ratio is currently 0.9 days.

OS Therapies Stock Performance

Shares of OSTX traded down $0.02 during mid-day trading on Friday, hitting $1.36. 417,684 shares of the company traded hands, compared to its average volume of 684,399. OS Therapies has a 1 year low of $1.12 and a 1 year high of $2.98. The stock has a 50-day moving average price of $1.60 and a two-hundred day moving average price of $1.84. The stock has a market cap of $47.89 million, a price-to-earnings ratio of -1.66 and a beta of -3.79.

OS Therapies (NYSEAMERICAN:OSTX) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.21) earnings per share for the quarter. On average, analysts forecast that OS Therapies will post -0.64 EPS for the current year.

Institutional Investors Weigh In On OS Therapies

Hedge funds and other institutional investors have recently made changes to their positions in the business. Millennium Management LLC purchased a new position in shares of OS Therapies in the third quarter worth approximately $183,000. Two Sigma Investments LP bought a new position in OS Therapies in the third quarter worth approximately $169,000. Virtu Financial LLC boosted its stake in shares of OS Therapies by 252.0% during the 3rd quarter. Virtu Financial LLC now owns 75,801 shares of the company’s stock worth $149,000 after acquiring an additional 54,269 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of OS Therapies during the 2nd quarter valued at $63,000. Finally, Bridgeway Capital Management LLC purchased a new stake in shares of OS Therapies in the 2nd quarter worth $47,000.

Wall Street Analyst Weigh In

Several brokerages recently commented on OSTX. D. Boral Capital reissued a “buy” rating and set a $20.00 price objective on shares of OS Therapies in a research report on Monday, January 5th. Zacks Research upgraded shares of OS Therapies from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 11th. Finally, Lake Street Capital cut their price target on shares of OS Therapies from $18.00 to $17.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. Two analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $18.50.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.